Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jesse Hanks

Physician Assistant Jackson, MS Physician Assistant

NPI 1306434477 CMS profile 11021363

501 Marshall St Ste 600, Jackson, MS 39202

Open in the dashboard

General payments

$8,024

178 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jesse Hanks of Jackson, MS is reported in the CMS Open Payments database as having received $8,024 across 178 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $498 19
2024 General $2,329 43
2023 General $533 34
2022 General $2,124 36
2021 General $2,540 46

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jesse Hanks
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Jesse Hanks were reported at $498. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Jesse Hanks Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $2,540 $132 $37–$438 $132
2022 $2,124 $155 $48–$522 $149
2023 $533 $167 $52–$557 $160
2024 $2,329 $178 $55–$600 $164
2025 $498 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Axonics Modulation Technologies, Inc. $6,415 100 payments
  2. Sumitomo Pharma America, Inc. $799 43 payments
  3. Astellas Pharma US Inc $224 8 payments
  4. Boston Scientific Corporation $147 1 payment
  5. Allergan Inc. $129 10 payments
  6. AbbVie, Inc. $123 6 payments
  7. Urovant Sciences Inc $57 3 payments
  8. Coloplast Corp $43 2 payments
  9. Hologic, LLC $26 1 payment
  10. Provepharm Inc. $21 1 payment
  11. Other $40 3 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,348 165 payments
  2. Travel and Lodging $3,471 9 payments
  3. Education $126 3 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $79 1 payment
Products named General payments · program years 2021–2025
  1. Axonics $4,251 73 payments
  2. Axonics r-SNM System $2,170 27 payments
  3. GEMTESA $856 46 payments
  4. Bulkamid $307 5 payments
  5. BOTOX Hyperhydrosis $161 12 payments
  6. MYRBETRIQ $124 7 payments
  7. BOTOX Botox Therapeutic $60 3 payments
  8. Restorelle $43 2 payments
  9. LILETTA $31 1 payment
  10. BLUDIGO $21 1 payment
  11. Other $49 3 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

1,515

Median for Physician Assistant: 241

Drug cost

$474,950

Median for Physician Assistant: $4,110

Branded share of claims

71.6%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gemtesa Vibegron Brand 401 $260,753
Myrbetriq Mirabegron Brand 287 $183,420
Estradiol Generic 337 $22,301
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 202 $1,918
Estradiol (Twice Weekly) Estradiol Brand 16 $1,575
Nitrofurantoin Nitrofurantoin Macrocrystal Brand 62 $1,501
Yuvafem Estradiol Brand 15 $970
Fosfomycin Tromethamine Generic 13 $855
Oxybutynin Chloride Er Oxybutynin Chloride Brand 17 $353
Clobetasol Propionate Generic 17 $350

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 44 billing codes

Paid by Medicare

$141,666

Of which drugs: $8,962

Medicare patients

788

Average age 76

Services billed

8,284

788 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 65%
Diabetes 29%
Depression 28%
Osteoporosis 26%
Ischemic heart disease 23%
Chronic kidney disease 15%
COPD 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 17 1,700 $8,507
Injection, heparin sodium, per 1000 units J1644 Office 51 1,901 $348
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 51 1,094 $93

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
GEMTESA
  • Sumitomo Pharma America, Inc. $327
$327 401 —
BOTOX
  • AbbVie, Inc. $18
$18 — 1,700

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

178 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record